⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL263398 | 0.81 | ALDH1A1 (0.45) | — | |
| SCHEMBL27748701 | 0.80 | — | — | |
| Iodide SCHEMBL28449438 | 0.79 | ALDH1A1 (0.44) | — | |
| SCHEMBL15437081 | 0.78 | HSD17B10 (0.36) | — | |
| SCHEMBL2244526 | 0.78 | — | — | |
| SCHEMBL18256087 | 0.78 | ALDH1A1 (0.43) | — | |
| SCHEMBL755570 | 0.77 | — | — | |
| SCHEMBL13458766 | 0.76 | — | — | |
| SCHEMBL4295925 | 0.76 | — | — | |
| SCHEMBL1846903 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346564-A1 | INHIBITORS OF PARG | ARASE THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12227484-B2 | Inhibitors of PARG | ARASE THERAPEUTICS INC. (US) | 2025-02-18 | — | — | US | disclosed |
| EP-4479387-A1 | INHIBITORS OF PARG | ARase Therapeutics Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| CN-119013261-A | Inhibitors of PARG | 雅瑞斯医疗公司 | 2024-11-22 | — | — | CN | disclosed |
| WO-2023175184-A1 | 2,4-DIOXO-1,4-DIHYDROQUINAZOLINE DERIVATIVES AS PARG INHIBITORS FOR THE TREATMENT OF CANCER | FORX THERAPEUTICS AG (CH) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023175184-A1 | 2,4-DIOXO-1,4-DIHYDROQUINAZOLINE DERIVATIVES AS PARG INHIBITORS FOR THE TREATMENT OF CANCER | FORX THERAPEUTICS AG (CH) | 2023-09-21 | — | — | WO | disclosed |
| US-20230265057-A1 | INHIBITORS OF PARG | ARASE THERAPEUTICS INC. | 2023-08-24 | — | — | US | disclosed |
| WO-2023154913-A1 | INHIBITORS OF PARG | ARASE THERAPEUTICS INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| CN-111225915-B | Imidazopyridine compounds as PAD inhibitors | 朱比兰特埃皮帕德有限公司 | 2023-03-07 | — | — | CN | disclosed |
| EP-3697785-B1 | IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC (US) | 2022-12-28 | — | — | EP | disclosed |
| US-20020161237-A1 | Dehydroamino acids | HOFFMANN-LA ROCHE INC. | 2002-10-31 | — | — | US | disclosed |
| WO-2002055491-A2 | 1,2-DISUBSTITUTED CYCLIC INHIBITORS OF MATRIX METALLORPROTEASES AND TNF-$g(a) | BRISTOL MYERS SQUIBB COMPANY P (US) | 2002-07-18 | — | — | WO | disclosed |
| US-6403632-B1 | CYCLIC AMIDE DERIVATIVE | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2002-06-11 | — | — | US | disclosed |
| EP-1186604-A1 | BENZAZEPINE DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-03-13 | — | — | EP | disclosed |
| EP-1162196-A1 | FUSED-RING COMPOUNDS AND USE THEREOF AS DRUGS | JAPAN TOBACCO INC. (JP) | 2001-12-12 | — | — | EP | disclosed |
| WO-2001058853-A1 | DEHYDROAMINO ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-16 | — | — | WO | disclosed |
| US-6204293-B1 | INHIBITING POST-TRANSLATIONAL MODIFICATION OF THE ONCOGENIC RAS PROTEIN BY PROTEIN FARNESYLTRANSFERASE, PROTEIN GERANYLGERANYLTRANSFERASE, OR BOTH | UNIVERSITY OF PITTSBURGH | 2001-03-20 | — | — | US | disclosed |
| CN-1272841-A | Novel lactam metalloprotease inhibitors | DU PONT PHARM CO (US) | 2000-11-08 | — | — | CN | disclosed |
| US-6057336-A | ANTIINFLAMMATORY AGENTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-05-02 | — | — | US | disclosed |
| WO-1998050031-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1998-11-12 | — | — | WO | disclosed |